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Abstract 
Background: The prognosis of acute megakaryoblastic leukemia (AMKL) is really dismal, which urges for develop-
ment of novel treatment. Baicalein is one type of flavonoids extracted from Scutellaria baicalensis Georgi (Huang Qin). 
It inhibited cell proliferation and subcutaneous tumor formation of many tumor cell lines. However, whether baicalein 
possesses anti-AMKL activities has not been tested.
Results: We found that baicalein potently inhibited proliferation of multiple AMKL cells including CMK, CMY, Y10, 
6133, and 6133 MPL/W515L due to apoptosis and cell cycle arrest at G1 phase. Unexpectedly, caspase inhibitor z-VAD-
fmk did not restore cell proliferation. In contrast, ectopic expression of Cyclin D1 efficiently antagonized the inhibitory 
effect of baicalein. In addition, baicalein induced differentiation of 6133 MPL/W515L cells. Finally, baicalein promoted 
mice survival and reduced disease burden in a mouse model of AMKL.
Conclusions: Baicalein possesses potent anti-AMKL activity in vitro and in vivo. Baicalein may be a potent reagent for 
AMKL therapy.
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Background
Acute megakaryoblastic leukemia (AMKL) is a rare sub-
type of acute myeloid leukemia classified as M7 by FAB 
[1–3]. Representing approximately 1  % of all leukemia 
during childhood, AMKL is the most common type of 
acute myeloid leukemia (AML) in young children with 
Down syndrome with an incidence of 0.5 per million 
per year [4]. GATA-1 mutations are tightly associated 
with AMKL in Down Syndrome children and sporadic 
mutations have found in adult AMKL [5, 6]. The only 
recurrent genetic alterations identified were OTT-MAL 
and CBFA2T3-GLIS2 in children type of AMKL [7–9]. 
Although intensive multidrug chemotherapy has been 
employed, the prognosis of AMKL is really dismal with 
median survival time 40 weeks [10–12]. So far, no target 
therapy is available for AMKL. Recently, Aurora kinase 
A was proposed to be a therapeutic target for chemicals 
such as MLN8237 to promote polyploidization and dif-
ferentiation in AMKL, shedding a light on target therapy 
of this fatal disease [13]. Nevertheless, it is still early to 
warrant a successful clinical result and the poor situation 
urges for the development of novel therapeutic methods.
Traditional Chinese herbs have been recognized as a 
good resource for drug development. Among them, bai-
calein is very attractive for its anti-inflammatory, anti-
microbial, neuro-protective, and anti-cancer properties 
[14]. Baicalein is one type of flavonoids isolated from the 
dried root of Scutellaria baicalensis Georgi (Huang Qin). 
It has been reported to inhibit proliferation and induce 
apoptosis in various human cancer cell lines, such as liver, 
colon, breast, lung, myeloma, and pancreatic cancer cells 
[15–19]. Previous studies suggest baicalein and other two 
closely related flavonoids (wogonin and baicalin) may 
inhibit proliferation and induce apoptosis mainly through 
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causing cell cycle arrest, modulating activities of some 
important signaling molecules including AKT, IκB-α,p53, 
and notch. [18, 20–22], promoting reactive oxygen spe-
cies (ROS) product, releasing cytochrome c, regulating 
mitochondrial membrane potential, or activating caspase 
cascade [23–25]. Yet very few studies have been done 
in leukemic cells. Recently, wogonoside was reported to 
improve survival of NOD/SCID mice xenografted with 
AML blasts [26]. Thus these flavonoids may possess great 
potential for development of anti-leukemia drugs.
In the present study, we investigated the effects of bai-
calein on AMKL cells. We found that baicalein potently 
inhibited AMKL cell proliferation in  vitro by inducing 
cell cycle arrest. In vivo, baicalein reduced disease bur-
den and promoted mouse survival in an AMKL mouse 
model. Our study identified baicalein as a potent chemi-
cal compound that may be beneficial for AMKL therapy.
Results
Baicalein potently inhibits proliferation of AMKL cells
To test the effect of baicalein on AMKL cell proliferation, 
multiple AMKL cell lines including CMK, CMY, Y10, 
and 6133 were treated with baicalein and the cell prolif-
eration was measured. We found that baicalein efficiently 
inhibited cell proliferation in a concentration- and time-
dependent manner (Fig. 1a). 6133/MPL W515L cells were 
derived from 6133 with MPL W515L overexpression. 
These cells proliferated without SCF (stem cell factor) 
and caused AMKL in mice [27]. Apparently, these cells 
retained the sensitivity to baicalein treatment similar to 
6133 cells (Fig. 1a). We also tested its effect on other types 
of leukemic cells and observed similar results (Fig.  1b). 
These observations suggest that baicalein is a potent anti-
leukemia reagent. In this study, we focused on AMKL and 
used 6133 and 6133/MPL W515L cells as models.
Baicalein induced apoptosis in AMKL cells
To explore how baicalein reduced AMKL cell proliferation, 
we measured cell death after baicalein treatment. As shown 
in Fig.  2a, baicalein treatment induced apoptosis evi-
denced by increased Annexin V staining and the cleavage 
of caspase 3 (Fig. 2a, b). Although caspase inhibitor Z-VAD 
reduced the protein level of cleaved caspase 3, Z-VAD 
treatment did not significantly reduce baicalein-induced 
apoptosis (BAI vs BAI + z-VAD) (Fig. 2c, d). Accordingly, 
Z-VAD treatment failed to restore cell proliferation inhib-
ited by baicalein (BAI vs M BAI + Z-VAD) (Fig. 2e). These 
results suggest that caspase activation may not be the major 
cause of cell proliferation inhibition by baicalein.
Baicalein causes cell cycle arrest at G1/G0 phase
To further determine whether baicalein caused cell pro-
liferation inhibition by inducing cell cycle arrest, we first 
analyzed cell cycle profiles by DAPI staining in 6133 MPL 
W515L cells treated with baicalein. We found that bai-
calein treatment significantly reduced the percentage of 
cells at S phase and increased the percentage of cells at 
G1 phase (Fig.  3a). Consistent to cell cycle profile, bai-
calein treatment dramatically elevated the expression of 
CDK inhibitors p21 and p27 and reduced the expression 
of Cyclin D1 (Fig. 3b, c). We further tested whether Cyc-
lin D1 overexpression may overcome cell proliferation 
inhibition by baicalein. As expected Cyclin D1 overex-
pression promoted cell proliferation. More importantly, 
Cyclin D1 overexpression efficiently rescued the cell pro-
liferation inhibition, especially at 10  μM concentration 
(Fig. 4a). In consistent, Cyclin D1 overexpression rescued 
cell cycle arrest and cell apoptosis induced by baicalein 
(Fig.  4b, c). These observations suggest that cell cycle 
arrest may play a major role in baicalein-induced cell 
proliferation inhibition.
Baicalein induces AMKL cell differentiation and possesses 
anti‑AMKL potential in vivo
To test whether proliferation inhibition by baicalein was 
accompanied by cell differentiation, we measured CD41 
expression. Baicalein treatment significantly augmented 
CD41 expression (Fig. 5a). 6133/MPL W515L cells have 
been shown to induce AMKL in mice and compounds 
that forced megakaryocyte differentiation possessed 
potent therapeutic effect on AMKL [8, 9, 13, 27]. To test 
the effect of baicalein on AMKL in vivo, we transplanted 
6133/MPL W515L (carrying GFP for tracing) into sub-
lethally irradiated mice and treated mice with baica-
lein. 2  days after transplantation, the engraftment was 
confirmed by monitoring the GFP+ in peripheral blood 
from recipient mice (data not shown). Mice were then 
randomly divided into two groups for baicalein or vehi-
cle treatment. We found that baicalein treatment signifi-
cantly promote mice survival (Fig. 5b). Pathology analysis 
revealed that baicalein significantly reduced blood cell 
infiltration in spleen and lung (Fig. 5c). In another set of 
experiment, baicalein also reduced the weight of spleen 
compared with vehicle treated mice 2 weeks after trans-
plantation (Fig.  5d). These results suggest that baicalein 
may possess anti-AMKL function.
Discussion
The prognosis of AMKL is very dismal partially due to 
failure to identify recurrent genetic alterations for target 
therapy that urges for development of novel therapeu-
tic methods. Recently, OTT-MAL and CBFA2T3-GLIS2 
have been identified as two recurrent genetic alterations 
in children type of AMKL and compounds forcing mega-
karyocyte differentiation possessed potent therapeutic 
effect in AMKL [8, 9, 13]. In this study, we showed that 
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Fig. 1 Baicalein inhibited proliferation of leukemia cells. a AMKL cell lines (CMK, CMY, Y10, 6133 and 6133 MPL/W515L) and b other types of leuke-
mic cells (Raji, U937 HL60, Jurkat and K562) were treated with or without baicalein (0, 10, and 20 µM). The cell numbers of viable cells were deter-
mined every 24 h by counting the trypan blue-excluding cells. The cell numbers were normalized to the starting cell number (day 0) and presented 
as proliferation rate. Data were statistics (Mean ± SD) of a representative experiment (triplicates) from three independent experiments with similar 
results. *, **, or *** indicates significance (p < 0.05, 0.01, 0.001, respectively) compared to vehicle treatment
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baicalein possessed anti-AMKL abilities in  vitro and 
in vivo and might be a potent compound for developing 
novel AMKL therapy.
Although many previous studies have shown the anti-
proliferation or anti-tumor functions of baicalein or 
other similar bioactive components of Scutellaria such 
as wogonin and baicalin in many types of cancer cells, 
their functions in leukemia cells have not be well char-
acterized. In one study, baicalein inhibited myeloma cell 
proliferation by suppressing IL-6 signaling [28]. Baica-
lin induced apoptosis by inducing ROS while wogonin 
caused apoptosis, inhibited PKC signaling, and inducing 
differentiation [24, 29]. In our study, we showed baica-
lein suppressed AMLK cell proliferation by inducing cell 
cycle arrest and differentiation. Although ROS seemed 
to be induced by baicalein, the ROS scavenger NAC 
(N-acetyl-l-cysteine) did not antagonize the inhibitory 
effect of baicalein on leukemia cell proliferation (data not 
shown). Considering all these observations, it is possible 
that baicalein may affect multiple targets and the mecha-
nism by which baicalein exert its function depending on 
cell context [24, 29–31].
Other mechanism may exist for baicalein to inhibit 
AMKL cell proliferation. We noticed previous study 
Fig. 2 Baicalein induced apoptosis in 6133 MPL/W515Lcells. a 6133 MPL/W515L cells were treated with or without baicalein (0, 10, and 20 µM) for 
12 h and subjected for Annexin V staining (PE-conjugated antibody) to measure apoptosis. b The treated cells were collected for western blot to 
detect cleaved caspase 3 as an apoptotic marker. Hsc70 serves as a loading control. c 6133 MPL/W515L cells were treated with or without baicalein 
and Z-VAD in combination as indicated for 24 h. The treated cells were collected for western blot to detect cleaved caspase 3 as an apoptotic 
marker. d 6133 MPL/W515L cells were treated with or without baicalein (BAI, 10 µM) and Z-VAD (10 µM) in combination as indicated for 24 h. The 
treated cells were collected for Annexin V staining to measure apoptosis. e The treated cells numbers were counted after 24 h (day 1) and 48 h (day 
2) and the proliferation rate was presented. Data were statistics (Mean ± SD) of a representative experiment (triplicates) from three independent 
experiments with similar results. *p < 0.05, **p < 0.01and ***p < 0.001 as compared to vehicle treatment
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showing that baicalein activated Notch signaling in K562 
cells [22]. Notch signaling was critical for early stage of 
megakaryocyte commitment and dysregulation of Notch 
signaling by OTT-MAL caused AMKL through bind-
ing to RBPJ, one downstream targets of Notch signal-
ing. These observations suggest Notch signaling may 
be a common pathway for targeting in leukemia. In our 
model, the 6133 cells were derived from OTT-MAL 
knock-in mice developing AMKL. It is possible and wor-
thy to investigate if baicalein may induce megakaryocyte 
differentiation and inhibit cell proliferation by modulat-
ing endogenous Notch signaling in AMKL cells.
Conclusions
Baicalein induced AMKL cells growth inhibition and 
apoptosis in  vitro, cell cycle arrest may be the key 
mechanism. Baiclein can relieve disease burden in vivo. 
Baicalein may be a potent reagent for auxiliary AMKL 
therapy.
Methods
Cell culture and chemical compounds
CMK, CMY, Y10, 6133 MPL/W515L (AMKL cell lines), 
Raji (human lymphoma cell line), U937 (human mac-
rophage cell line), HL60 (human promyelocytic leukemia 
Fig. 3 Baicalein caused cell cycle arrest in the G1 phase. a Cells were treated with or without baicalein (0, 10, and 20 µM) for 24 h and collected 
for DAPI staining and FACS analysis. The cell cycle profile was analyzed with a Flowjo software. b, c The treated cell were collected to measure the 
mRNA expression level of p21 and p27 and protein expression level of Cyclin D1. *p < 0.05, **p < 0.01 and ***p < 0.001 as compared to vehicle treat-
ment. HSC70 was used as internal control
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Fig. 4 Cyclin D1 overexpression antagonized the effect of baicalein on cell proliferation, apoptosis, and cell cycle. 6133 cells transduced with Cyclin 
D1 or control vector were treated with or without baicalein (0, 10, and 20 µM). a The cell proliferation, b cell cycle, and c apoptosis were measured 
as described above. *p < 0.05, **p < 0.01 and ***p < 0.001 as compared to vehicle treatment
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cells), Jurkat (acute T cell leukemia), K562 (chronic mye-
logenous leukmia), and HEL (human erythroleukemia 
cell) cells were cultured in RPMI-1640 media containing 
10 % fetal bovine serum (FBS) and 1 % penicillin–strepto-
mycin (Invitrogen, Carlsbad, CA, USA). 6133 cells were 
cultured in RPMI-1640 media supplemented with 1  % 
KIT Ligand conditioned medium as previously described 
[32]. Baicalein was purchased from Shanxi Ciyuan Bio-
tech Co., Ltd (Xi’an, China). z-VAD-fmk was purchased 
from EMD Millipore (Billerica, MT, USA). DAPI and 
NAC (N-acetyl-l-cysteine) were purchased from Sigma 
(St. Louis, MO, USA).
Cell proliferation assay
Cells (5 × 105 cells/well) were seeded in a 12-well plate. 
Drugs were added to the medium at the various concen-
trations as indicated. After 24 and 48 h incubation, cells 
were stained with Trypan blue and the Trypan blue-
excluded live cells were counted under a light micros-
copy. The cell numbers were normalized to the starting 
cell number and presented as proliferation rate. All cell 
proliferation curves were statistics of one representative 
experiment (triplicates) from three independent experi-
ments with similar results.
Cell cycle profiling
Cell cycle profile was assayed by staining with DAPI. 
Briefly, baicalein-treated cells were fixed, permeablized, 
and stained with 10  μg/ml DAPI. Data were acquired 
through Flow Cytometry and the cell cycle profile was ana-
lyzed by a FlowJo software (Tree Star,). Flow cytometry was 
performed on a Calibur (BD Biosciences, Franklin Lakes, 
NJ, USA) and data were analyzed by a FlowJo software.
Western blot analysis
Western blot analysis was performed as previously 
described [32]. Membranes were blotted with antibod-
ies detecting cleaved caspase-3, Cyclin D1, and HSC70. 
Cleaved caspase-3 and Cyclin D1 antibodies were pur-
chased from Cell Signaling Technologies. HSC70 and 
horseradish peroxidase-conjugated secondary antibody 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). DAPI and Annexin-V flow antibody were 
purchased from BD.
Quantitative RT‑PCR
The quantitative RT-PCR was performed as previously 
described [33]. The PCR primer sets used to detect p21 
and p27 were as following:
Fig. 5 Baicalein possesses anti-AMKL activity in vivo. a 6133 MPL/W515L cells treated with or without baicalein were collected for CD41 staining. 
The expression of CD41 was analyzed by flow cytometry. b Sublethally irradiated mice were transplanted with 6133 MPL/W515L cells (3 × 105 cells/
mouse). Two days after transplantation, the recepient mice were fed with vehicle or baicalein (20 mg/kg body weight) through oral gavage for 
10 days and left for survival observation. c The spleen weight from the recipient mice sacrificed on 14 days post transplantation (n = 3, *indicates 
p < 0.05). d Histological sections of the spleen and lung from recipient mice sacrificed on 14 days post transplantation were stained with Hematoxy-
lin and eosin (H and E). *p < 0.05 as compared to vehicle treatment
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p21: sense 5-ACCAGCCTGACAGATTTCTA-3 and 
antisense 5-TGACCCACAGCAGAAGAG-3; P27: sense 
5-AGTGTCCAGGGATGAGGA-3 and antisense 5-GG 
GAACCGTCTGAAACAT-3. The internal control using 
the primers were: GAPDH: sense 5-GGTGAAGGTCG 
GTGTGAACG-3 and antisense 5-CTCGCTCCTGGA 
AGATGGTG-3.
Retroviral transduction
For Cyclin D1 overexpression, retrovirus (pMIGR1) was 
used. The retroviral stocks were prepared as previously 
described and used for infection of 6133 cells [32]. We 
obtain 6133 cells with stable expression of Cyclin D1 by 
flow cytometry sorting GFP + cells.
AMKL mouse model
AMKL mouse model was established as previously 
described [13]. Briefly, recipient mice were suble-
thally (600  rad) irradiated and 6133/MPL W515L cells 
(3 ×  105) were introduced into recipient mice through 
tail vein injection. Two days after injection, mice were 
randomly divided into control and experiment groups 
and received vehicle or baicalein (20 mg/kg body weight) 
through oral gavage for 10 days. Mice were sacrificed on 
day 14 for disease burden analysis or maintained to end 
point for survival rate analysis. Log-rank (Mantel-Cox) 
test was performed to measure the statistic significance 
of the difference between vehicle and baicalein treat-
ment groups. All procedures involving animals were 
approved by the Animal Care and Use Committee of 
Wuhan University.
Statistical analysis
Student’s t-test (unpaired, two-tail) was used for sta-
tistical analysis and a p value  <0.05 was considered as 
significance.
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